Global Juvenile Macular Degeneration (Stargardt Disease) Market: Information by Diagnosis (Fluorescein Angiography and others), Management (Magnifying Spectacles and others), End User (Hospital & Eye Clinics and others) and Region - Forecast till 2027
Sample Report: https://www.marketresearchfuture.com/sample_request/4935
Market Highlights
Eye care has become one of the important aspects of medicine due to the continuous development of new therapies and availability of technologically advanced devices for eye care. Furthermore, the prevalence of eye disease is found to be increasing for all ages. Macular degeneration diseases such as Best disease and Stargardt disease are found to be highly prevalent among the children. Market players are now focusing on the development of novel therapies such as stem cell therapy to reduce the supply-demand gap in the market. Eye care supplement act as a protective measure whose demand is found to be increasing in the developing countries across the globe. Additionally, increasing demand for early diagnosis and treatment is boosting the market growth.
Global Juvenile Macular Degeneration (Stargardt Disease) market is expected to grow at a CAGR of 7.2% during the forecast period 2017-2023.
Key Players in Global Juvenile Macular Degeneration Market Acucela Inc. (U.S.), Alkeus Pharmaceuticals Inc. (U.S.), Astellas Pharma Inc. (Japan), ProQR Therapeutics NV (Netherland), Sanofi (France), Bayer HealthCare (Germany), F. Hoffmann-La Roche (Switzerland), Copernicus Therapeutics Inc. (U.S.), Grupo Ferrer Internacional SA (U.S.), Iris Pharma (U.S.), Nemus Bioscience Inc (U.S.), Ophthotech Corp (U.S.), Iconic Therapeutics (U.S.), Adverum Biotechnologies (U.S.), PanOptica (U.S.), RXi Pharmaceuticals (U.S.), Neurotech Pharmaceuticals (U.S.)
The European juvenile macular degeneration market accounted for 32.7% market share in 2016. In Europe, Germany, the U.K, and France are the largest contributors to the market owing to the availability of funds for research, and extensive research and development activities in ophthalmology. The development of novel therapies and other treatment options for juvenile macular degeneration also fuel the growth of the market. The Middle East & Africa exhibit steady but positive growth owing to low technology penetration in developing regions of Africa, and increasing demand for diagnostics services in developing regions. In the Middle East, the United Arab Emirates accounts for the largest market share for macular degeneration.
About Us: Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Comments